Related Experiment Video
Updated: Sep 24, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases
Benjamin Steren1, Barbara Burtness2, Aarti Bhatia3
1Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven.
Purpose:
To review the demographics, clinical features, and response of orbital squamous cell carcinoma treated with cemiplimab.
Methods:
This is a retrospective multi-institutional series. Patient characteristics, drug dosing, duration, and response to treatment were evaluated.
Results:
The study cohort consisted of 11 patients from 5 institutions. All patients received a regimen of 350 mg q 3 weeks and an average of 11.2 cycles (SD 5.8). No patient experienced significant side effects requiring treatment or cessation of cemiplimab. Complete response was achieved in 9 patients (82%) treated with cemiplimab.
Conclusions:
Immune checkpoint inhibitors, such as cemiplimab provide a globe-sparing option for the treatment of orbital squamous cell carcinoma. It is important to consider these agents especially when orbital exenteration is the alternative.
